US20040092718A1 - Use of a CD28 binding substance for making a pharmaceutical composition - Google Patents

Use of a CD28 binding substance for making a pharmaceutical composition Download PDF

Info

Publication number
US20040092718A1
US20040092718A1 US10/389,679 US38967903A US2004092718A1 US 20040092718 A1 US20040092718 A1 US 20040092718A1 US 38967903 A US38967903 A US 38967903A US 2004092718 A1 US2004092718 A1 US 2004092718A1
Authority
US
United States
Prior art keywords
cells
mab
mabs
ser
thr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/389,679
Other languages
English (en)
Inventor
Thomas Hunig
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
TeGenero AG
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Assigned to TEGENERO AG reassignment TEGENERO AG ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: HUNIG, THOMAS
Publication of US20040092718A1 publication Critical patent/US20040092718A1/en
Priority to US11/585,484 priority Critical patent/US20070134240A1/en
Priority to US12/251,039 priority patent/US8389016B2/en
Priority to US13/783,959 priority patent/US20130266577A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Definitions

  • the invention relates to the use of a CD28 binding substance for making a pharmaceutical composition.
  • Monoclonal antibodies are antibodies which are produced by hybrid cell lines (so-called hybridomas) which typically have been generated by fusion of a B cell of animal or human origin producing antibodies with a suitable myeloma tumor cell.
  • the C′-D loop of CD28 comprises the amino acids 52 to 66 of the above CD28 sequence (for numbering see also Ostrov, D. A., et al.; Science (2000), 290:816-819).
  • the term C′-D loop will also include in the following any partial sequences therefrom.
  • a loop or a binding site arranged therein is freely accessible, if for a defined binding partner for the binding site in the loop there is no steric hindrance by the sequences or molecules following to the loop.
  • Regulatory T cells are CD4+ T cells inhibiting in a mixture with naive CD4+ T cells the activation thereof.
  • CD4+CD25+ T cells Another feature of regulatory T cells is, compared to other T cells, a low expression of the high-molecular isoforms of CD45 (human: RA).
  • RA human RA
  • CD4+CD8-SP thymocytes are one of the essential sources for regulatory T cells.
  • the induction of regulatory T cells is the increase of the metabolic activity, enlargement of the cell volume, synthesis of immunologically important molecules and beginning of the cell division (proliferation) upon an external stimulation. As a result, after the induction there are more regulatory T cells than before.
  • Homology is an at least 70%, preferably at least 80%, most preferably at least 90% sequence identity on a protein level, a homologous protein or peptide binding a defined binding partner with at least identical affinity. Deviations in the sequence may be deletions, substitutions, insertions and elongations.
  • a mimicry compound is a natural or synthetic chemical structure behaving in a defined binding assay as a defined mAb mimicrying the mimicry compound.
  • mAbs comprises, in addition to structures of the conventional Fab/Fc type, also structures exclusively consisting of the Fab fragment. It is also possible to use the variable region only, the fragment of the heavy chains being connected with the fragment of the light chain in a suitable manner, for instance also by means of synthetic bridge molecules, such that the binding regions of the chains form the antibody epitope.
  • the term antibody also comprises (possibly complete) chimeric and humanized antibodies.
  • Superagonistic stimulation of the proliferation of CD28-specific cells means that no costimulation, i.e. no further binding event in addition to a binding of a mAb or of a mimicry compound to CD28 is necessary for the stimulation or inhibition of the proliferation.
  • the activation of resting T cells for the proliferation and functional differentiation firstly requires the occupation of two surface structures, so-called receptors: 1. of the antigen receptor having a different specificity from cell to cell and being necessary for the detection of antigens, e.g. viral fission products; and 2. the CD28 molecule expressed on all resting cells with the exception of a sub-group of the human CD8 T cells, said CD28 molecule naturally binding to ligands on the surface of other cells of the immune system. This is called the costimulation of the antigen-specific immune reaction by CD28. In a cell culture, these processes can be imitated by occupation of the antigen receptor and of the CD28 molecule with suitable mAbs. In the classic system of the costimulation, neither the occupation of the antigen receptor nor that of the CD28 molecule alone will lead to the T cell proliferation, the occupation of both receptors is however effective. This observation has been made with T cells of man, mouse and rat.
  • CD28-specific mAbs that can initiate the T cell proliferation without costimulation.
  • Such a superagonistic, i.e. independent from the occupation of the antigen receptor, activation of resting T lymphocytes by CD28-specific mAbs is known in the art from the document Tacke et al., Eur. J. Immunol., 1997, 27:239-247.
  • CD28-specific monoclonal antibodies having different functional properties are described: costimulatory mAbs costimulating the activation of resting T cells only with simultaneous occupation of the antigen receptor; and superagonistic mAbs which can activate T lymphocytes of all classes in vitro and in the test animal for proliferation without occupation of the antigen receptor. Both in so far known mAbs originate from an immunization with cells, on which rat CD28 is expressed, and are obtainable by different selections directed to their respective properties.
  • TH1 and TH2 cells are CD4-expressing T cells.
  • TH1 cells are also called pro-inflammatory T helper cells and secern the cytokines IL-2, TNF and IFN- ⁇ .
  • TH2 cells support the activation of B cells and secern the cytokines IL-4, IL-5 and IL-10.
  • the differentiation of CD4 T cells from the above functionally different subgroups is not only controlled by the available cytokines, but it is also modulated by costimulation over CD28.
  • CD28-deficient mice show normal TH1, but reduced TH2-dependent answers and the cytokine profile of TCR transgenic CD4 cells is displaced by CD28 ligation in the direction TH2. On the other hand, a strong TCR signal will prevent CD28-mediated TH2 differentiation.
  • the Guillain-Barré syndrome is an acute autoimmune-inflammatory disease of the peripheral human nervous system.
  • the incidence of GBS is 1 to 2 per 100,000 inhabitants.
  • the chronic form is the chronic demyelinating polyneuropathy (CDP).
  • CDP chronic demyelinating polyneuropathy
  • the incidence of CDP is 10 to 20 per 100,000 inhabitants. mAbs or related substances for the prevention and/or treatment of these diseases are not known.
  • the invention is based on the technical object to specify a pharmaceutical composition, by means of which regulatory T cells can be stimulated and which is particularly suited for the prevention and/or treatment of the multiple sclerosis, type 1 diabetes, inflammatory intestinal diseases, GBS and/or CDP.
  • the invention teaches the use of a CD28-specific superagonistic monoclonal antibody (mAb) or of a mimicry compound thereto, for making a pharmaceutical composition for the induction and/or multiplication of regulatory T cells.
  • mAb monoclonal antibody
  • the invention is based on the finding that by means of superagonistic CD28-specific substances, mAbs or mimicry compounds hereto, CD4+CD25+ T cells can be induced, i.e. the number thereof is, after treatment of an organism with the substance, distinctly higher than in an organism that was not treated or was treated with non-superagonistic substances.
  • the invention is based on the finding that substances according to the invention obviously are very good drugs for the treatment of the Guillain-Barré syndrome and/or of the chronic demyelinating polyneuropathy and other autoimmune-related diseases. Therefore, the invention further teaches the use for treating these diseases.
  • Superagonistic CD28-specific substances used according to the invention i.e. mAbs or mimicry compounds thereto, are those which activate independently from the occupation of the antigen receptor several to all sub-groups of the T lymphocytes.
  • the substance binds to CD28 or to a partial sequence thereof.
  • the partial sequence may for instance include an amino acid sequence Seq. ID 1 or 2-7 or 17, which lie at least partially in the region of the C′-D loop of CD28.
  • amino acid sequence Seq. ID 1 or 2-7 or 17 which lie at least partially in the region of the C′-D loop of CD28.
  • amino acids of the sequence 8 may be connected in the order defined there.
  • the loop is in the region with the sequence GNYSQQLQVYSKTGF.
  • Mimicry compounds according to the invention can be identified in a screening method, a prospective mimicry compound or a mixture of prospective mimicry compounds being subjected to a binding assay with CD28 or a partial sequence herefrom, in particular the C′-D loop, and substances binding to CD28 or to the partial sequence herefrom being selected, possibly followed by an assay for testing for superagonistic stimulation of several to all sub-groups of the T lymphocytes.
  • a mixture it will be suitable to perform a deconvolution.
  • a ranking according to the selectivity and/or affinity may be established, highly affinitive substances being preferred.
  • a ranking may be performed according to a quantification of the induction of the regulatory T cells or according to the inhibition of the disease for instance in an animal test by using disease models.
  • An example of a substance used according to the invention is a superagonistic CD28-specific mAb. It can for instance be made by that a non-human mammal is immunized with CD28 or a peptide comprising a partial sequence herefrom, for instance as mentioned above or homologues hereto, cells being taken from the non-human mammal cells and hybridoma cells being produced from the cells, and the thus obtained hybridoma cells being selected such that in their culture supernatant there are mAbs binding to CD28.
  • a humanization can be performed with conventional methods. Suitable mAbs can alternatively be made by selecting B lymphocytes binding to the loop, and by cloning their expressed immunoglobulin genes. An isolation of suitable mAbs from phages libraries is also possible.
  • this may be a mAb being obtainable from hybridoma cells, as filed under the DSM numbers DSM ACC2531 (mAb: 9D7 or 9D7G3H11) or DSM ACC2530 (mAb: 5.11A or 5.11A1C2H3).
  • the mAb may comprise one or more of the sequences Seq. ID 9, 11, 13 and/or 15, or one or more of the sequences Seq. ID 10, 12, 14, 16, 18 and/or 19, or sequences being homologous hereto or being (partially) coded thereby.
  • Seq. ID 13 the nucleic acid sequence of the variable region of the heavy chain of a mAb 5.11A according to the invention is represented. Seq.
  • Seq. ID 14 shows the peptide coded thereby.
  • Seq. ID 15 shows the nucleic acid sequence of the variable region of the light chain of this mAb.
  • Seq. ID 16 is the peptide coded hereby.
  • Seq. ID 9 the nucleic acid sequence of the variable region of the light chain of a mAb 9D7 according to the invention is represented.
  • Seq. ID 10 shows the peptide coded hereby.
  • Seq. ID 11 shows the nucleic acid sequence of the variable region of the heavy chain of this mAb.
  • Seq. ID 12 is the peptide coded hereby.
  • Seq. ID 18 and 19 show the amino acid sequences of the variable region of a humanized mAb 5.11A of the light chain and of the heavy chain, respectively.
  • the invention finally also relates to treatments, wherein to a person suffering from a disease caused by low regulator T cell counts or high T lymphocytes infiltration in organs or tissues, for instance GBS and/or CDP, a pharmaceutical composition according to the invention is administered in a pharmacologically effective dose and in a galenic preparation suitable for the administration.
  • a pharmaceutical composition according to the invention is administered in a pharmacologically effective dose and in a galenic preparation suitable for the administration.
  • FIGS. 1 to 9 and the text sections belonging hereto methods and results are shown that represent on the one hand target structures for finding suitable substances and that describe on the other hand substances which can be used according to the invention.
  • FIGS. 10 to 15 are represented results that prove the induction of regulatory T cells by substances used according to the invention.
  • FIGS. 16 to 21 show results hat prove the effect of substances according to the invention in an animal model, the experimental allergic neuritis of the LEW rat (EAN).
  • the EAN is a model for the human GBS and the CDP (also called CIDP or chronic inflammatory demyelinating poly-radiculoneuropathy).
  • FIG. 1 the stimulation of T lymphocytes of the rat with different CD28-specific mAbs (a: costimulation, b: superagonistic stimulation),
  • FIG. 2 a sequence comparison between mouse, rat and human CD28 in the region of the C′-D loop (in box),
  • FIG. 3 experimental results for localizing the binding site of superagonistic mAb at the CD28 molecule of the rat
  • FIG. 4 the binding of different human CD28-specific mAbs at CD28 (a) and costimulatory (b) and superagonistic (c) activity of the mAbs of FIG. 4 a,
  • FIG. 5 binding tests that show that superagonistic mAbs specifically bind to the C′-D loop
  • FIG. 6 a three-dimensional representation of CD28 with marking of the C′-D loop
  • FIG. 7 experiments for the activation of cells by means of mAbs according to the invention
  • FIG. 8 the representation of the sequences Seq.-ID 9-16 (a-h) and of the humanized variable domain of the antibody 5.11A (light chain: VLC5.11, i; heavy chain: VHC5.11, j), Seq.-ID 18-19,
  • FIG. 9 the frequency of the CD4+CD25+ cells in the total population of the CD4 cells of a rat, in comparison to after a treatment with a superagonistic CD28-specific mAb and a costimulatory mAb,
  • FIG. 10 the phenotypic characterization of CD4+CD25+ cells induced by superagonistic CD28-specific mAbs and the comparison with CD4+CD25 ⁇ and CD4+CD25+ cells from untreated control animals,
  • FIG. 11 the induction of the proliferation of CD4+CD25+ cells by superagonistic CD28-specific mAbs in a cell culture
  • FIG. 12 another phenotype of the CD4+CD25+ cells obtained according to FIG. 11,
  • FIG. 13 the inhibitory function of the regulatory T cells
  • FIG. 14 the experiments according to FIG. 11 with human T cells and the use of superagonistic human-CD28-specific mAbs
  • FIG. 15 the course of the active EAN disease under treatment with superagonistic CD28-specific mAbs in comparison with costimulatory mAbs
  • FIG. 16 the effect against ENA by administration of superagonistic CD28-specific mAbs before the immunization with the autoantigen inducing EAN
  • FIG. 17 the treatment according to FIG. 15, however with a different treatment plan
  • FIG. 18 the treatment according to FIG. 15, however for the case of the passive or adoptive transfer EAN
  • FIG. 19 the sorting of human CD4+ cells in CD4+CD25+++ and CD4+CD25 ⁇ cells
  • FIG. 20 the growth curves of T cells expanded by monoclonal antibodies and IL-2 according to the invention of FIG. 19 (sorted),
  • FIG. 21 the CTLA-4 expression of the expanded T cells of FIG. 20, and
  • FIG. 22 the functional analysis of the expanded T cells of FIG. 20 by means of a suppression assay, A: proliferation of the indicator cells without and with stimulation (CD3/anti CD28), B: suppression of the proliferation of the indicator cells in presence of expanded CD4+CD25+++ cells.
  • FIG. 1 shows the stimulation of freshly isolated T lymphocytes of the rat in the form of a 3H thymidine incorporation.
  • the method corresponds to the one described in the document WO98/54225, to which here and in the following explicitly reference is made and its disclosure contents are herewith incorporated in the present text.
  • TCR T cell receptor
  • FIG. 1 a is shown the costimulation, i.e. T cell receptor (TCR) specific mAbs were bound to the plastic surface in all wells. Because of lacking costimulation, the negative control (uppermost bar) does not show any incorporation. Costimulation is then given by the addition of CD28-specific mAbs in a dissolved form. The complete shown range of CD28-specific mAbs was used.
  • CD28-specific mAbs originates from an approach of the immunization and preparation of hybridoma cell lines described in WO98/54225. These are culture supernatants containing enough CD28-specific mAbs for a saturating binding to 2 ⁇ 10 5 T cells. From FIG. 1 a can be taken that all of these mAbs are able to activate in a costimulating manner, i.e. to excite the thymidine incorporation in presence of the anti-TCR mAbs. In FIG. 1 b is shown the stimulation in absence of TCR-specific mAbs. This experiment, too, was performed as described in WO98/54225. It can be seen that only two mAbs are able to stimulate the T lymphocytes in absence of a TCR signal. These mAbs have thus a superagonistic activity.
  • CD28-specific mAbs bind to different regions of the CD28 molecule.
  • the mAbs were prepared by immunization of mice with CD28 of the rat; as expected, they all do not react with mouse CD28 (not shown). Since the mAbs can thus detect only such regions of the rat CD28 molecule which are different from the mouse, first a sequence comparison between the CD28 of the mouse and of the rat was made (see FIG. 2, upper section). The differences between the two species are highlighted. For identifying the amino acids, a one-letter code was used. As prototypes for a conventional rat CD28-specific mAb JJ319 was used, for a superagonistic mAb JJ316 was used (see WO98/54225).
  • FIG. 3 In FIG. 3 is shown the mapping of the binding. Expression plasmids were constructed, wherein a part of the extracellular domain of CD28 originates from the mouse, another one from the rat. This is symbolically shown by bars or lines; on the right hand thereof is shown the binding of the mAbs JJ316 and JJ319 to mouse fibroblasts (L929 cells) transfected with these expression plasmids. In the first two lines of FIG. 3 (m/r and r/m 1-37) the binding of the two antibodies to the “right-hand” half of the sequence is mapped. Both bind, when the latter originates from the rat. In the reversed construct (m/r CD28 1-37, left hand rat, right hand mouse) there is no binding.
  • mice were immunized with human-CD28-transfected A20/J mouse B lymphoma cells (see WO98/54225) and in addition boostered prior to the fusion with commercially available human-CD28 FC fusion protein (bought from R and D Systems).
  • human-CD28-specific mAbs binding to mouse L929 cells expressing human-CD28, but not to untransfected L929 cells, analogously to the screen in document WO98/54225.
  • FIG. 4 a shows that the used preparations of the three new mAbs bind comparatively well and also with a comparative titer to human T lymphocytes. It is shown an experiment wherein freshly isolated mononuclear cells from the human blood (so-called PBMC) firstly were treated with different dilution steps of the used mAbs on ice; then they were washed, and the bound mAb was made visible by a secondary antibody marked with a fluorescence dye, said antibody specifically detecting the bound mouse mAb.
  • PBMC mononuclear cells from the human blood
  • MFI is the median fluorescence intensity being a measure for the amount of the bound CD28-specific mAb.
  • concentrations are 1:3 dilutions of a standardized original preparation. It is fully normal that in this test the highest concentration provides a weaker signal than the following titration steps; this has to do with the avidity (bivalent binding) of mAbs and does not play a role in the contexts discussed here.
  • FIGS. 4 b and c compare the capabilities of superagonistic human-CD28-specific mAbs to those of conventional CD28-specific mAbs—in presence and in absence of a TCR signal—to stimulate freshly isolated human T cells to growth. Again a 3H thymidine incorporation is shown, as described before for the rat.
  • FIG. 4 b the wells were coated with a mAb reacting with the human TCR/CD3 complex. Thus costimulation was measured. It can be seen that the proliferation does not occur without a costimulation with one of the mAbs (negative control), all three antibodies are however able to stimulate the cell division.
  • FIG. 4 c the procedure took place in absence of a TCR/CD3-specific mAb. Only the antibodies 9D7 and 5.11A could stimulate in a superagonistic manner.
  • this specific preparation of the reactivity is surprising and confirms to a full extent the finding derived from the experiments with rat CD28, namely that superagonistic mAbs must bind to a defined, namely this position of the molecule.
  • FIG. 6 is a three-dimensional model of the CD28 molecule.
  • the newly defined binding region is highlighted. It corresponds to the sequence in the box in FIG. 2.
  • the extracellular domain of CD28 structurally belongs to the immunoglobulin superfamily being characterized by two superimposed ⁇ -pleated sheets as a basic structure. The labeling of these bands follows a pattern given in the literature. It is important for the representation shown here that the region identified as an epitope for superagonistic CD28-specific mAbs in rat and mouse are designated “C′-D loop”.
  • mAbs with specificity for the C′-D loop of the CD28 molecule have superagonistic activity, that is, in the meaning of the document WO98/54225, can be used for the activation of T lymphocytes.
  • the superagonistic activity of C′-D loop-specific mAbs in rat and man shows that not the sequence of the epitope, but its position or shape is important.
  • FIG. 7 shows that without stimulation there is no IL-2 production (negative control). The stimulation with a T cell receptor-specific mAb induces IL-2 production (positive control).
  • FIG. 7 shows that without stimulation there is no IL-2 production (negative control). The stimulation with a T cell receptor-specific mAb induces IL-2 production (positive control).
  • FIG. 7 a shows the results when using the superagonistic mAb JJ316 of the rat
  • FIG. 7 b shows the results for the human C′-D loop-specific mAb 5.11A.
  • the respective cell lines are stimulated to IL-2 production.
  • the stimulation did however not take place by means of “conventional” CD28-specific mAbs, since they do not only bind to the C′-D loop, but cannot detect at all the construct, because they are specific for the rat or human-specific sequences which are not included in the construct.
  • FIG. 9 In FIG. 9 are shown dot plots, wherein every measured cell is represented by a dot.
  • the phenotypic characterization of the regulatory T cells takes place by the combination of the cell surface molecules CD4 and CD25.
  • the cell suspensions were incubated with correspondingly fluorescence dye marked monoclonal antibodies against CD4 and CD25, washed and examined in a flow cytophotometer for the binding of these antibodies.
  • the shown results were obtained three days after IP injection of a costimulatory (FIG. 9 a , JJ319) or superagonistic CD28-specific mAb (FIG. 9 b , JJ316). In the case of JJ319, approx.
  • CD4 T cells 7% of the CD4 T cells are also CD25-positive(4/(50+4)), which corresponds to not shown results in untreated animals. However, after treatment with JJ316, approx. 20% are CD4+CD25+ (10/(10+40)). Further, the level of the CD25 expression is by far higher than in the control animal. Such a high level is characteristic for regulatory T cells.
  • FIG. 10 shows a phenotypic characterization in a representation as a histogram.
  • the marker CD45RC was detected, a high-molecular isoform of the CD45 molecule being expressed strongly on naive CD4 T cells, however weakly on stimulated CD4 T cells. A weak expression is typical for regulatory T cells.
  • FIG. 10 a shows that most CD4+C25 ⁇ cells from untreated animals strongly express CD45RC. However, in the case of CD4+CD25+ cells from untreated animals, a strong expression takes place in a clear minority of all cells (FIG. 10 b ). In the case of the treatment with the superagonistic CD28-specific mAb (FIG.
  • the downward regulation of CD45CD45RC is even more distinct than in the case of FIG. 10 b .
  • the CD152 (CTLA-4) constitutively expressed by regulatory T cells is detected by staining. This staining must be performed, because of the intracellular localization of CD152, after permeabilization of fixed cells, and is therefore provided with an unspecific background. For verifying this, a so-called isotype control was performed, i.e. an intracellular staining with a mAb of the same immunoglobulin class, which however cannot detect anything specifically.
  • the specific CD152 proof is obtained by a displacement of the CD152 histogram with regard to the isotype control histogram.
  • CD4+CD25+ cells are isolated by electronic cell sorting either from untreated rats (FIG. 11 a ) or from rats treated with JJ316 (FIG. 11 b ) and cultivated in 96 well plates according to the state of the art.
  • the cell multiplication was measured by 3H thymidine incorporation between day 2 and 3 of the cultivation.
  • “( ⁇ ) ” means no stimulation
  • costimulation means stimulation with a non-superagonistic CD28-specific mAb (JJ319) and with the TCR-specific R73
  • JJ316 shows the superagonistic stimulation.
  • FIG. 11 a as well as 11 b show that regulatory cells do not react well upon costimulation, however well upon stimulation with a superagonistic CD28-specific mAb. Stimulation with mAbs used according to the invention shows also in a cell culture a considerable multiplication of regulatory T cells.
  • FIG. 13 shows a representation according to FIG. 10 f , however after in vitro stimulation with superagonistic CD28-specific mAbs (JJ316). An even stronger detectable CD152 expression can be seen.
  • FIG. 13 is shown the inhibitory function of regulatory T cells on Cd4+CD25 ⁇ T cells serving as indicator cells for the suppression effect.
  • costimulation R73+JJ319
  • CD25+ means electronically sorted CD4+CD25+ T cells from animals treated three days before with superagonistic CD28-specific mAbs (JJ316).
  • CD25 ⁇ represents the indicator cells.
  • CD25+/CD25 ⁇ means in FIG. 13 a that both cell populations were mixed with one another in identical parts. It can be seen that upon costimulation the CD25+ cells do not react with proliferation.
  • FIG. 13 b is represented a titration of the regulatory T cells by a mixture with indicator cells in different quantities. It can be seen that even with a ratio of regulatory to indicator cells of 1:16, suppression can still be observed. This shows the high effectivity of the regulatory cells stimulated with mAbs used according to the invention.
  • FIG. 14 shows a comparison of the reactions of human CD4+CD25 ⁇ T cells (naive cells) to CD4+CD25+ T cells (regulatory cells) in response to costimulation (anti-CD3+conventional anti-CD28 mAb) or to human-specific superagonistic CD28-specific mAbs (9D7 and 5.11A).
  • the experiments correspond to those described above for the rat. Beginning at the left-hand side, the first three groups show unstimulated controls (no 3H thymidine incorporation). These are all CD4+ T cells, then the CD25 ⁇ fraction gained by sorting and finally the CD25+ fraction gained by sorting. “med” means medium.
  • FIG. 15 is represented the course of the active EAN disease under treatment with various mAbs.
  • 7-8 weeks old female LEW rats (obtainable from Charles River Laboratories, Sulzfeld, Germany) were used.
  • the animals were immunized with a synthetic peptide corresponding to a part of the myelin protein P2 wrapping peripheral nerve fibers (amino acids 53-78 of the bovine P2 protein, 50 ⁇ l of a 0.5 mg/ml solution, inoculation in the foot balls).
  • a progressive paralysis develops which can be quantified according to a standardized scoring (King et al., Exp. Neurol., 87:9-19 (1985)).
  • FIG. 15 a shows a preparative therapy with superagonistic CD28-specific mAbs (JJ316) and FIG. 15 b a treatment with conventional mAbs (JJ319).
  • the application took place in 1 mg/animal doses IP either on the day of the P2 immunization (D0), at day 12 (D12), i.e. after beginning of the symptoms, or on both days.
  • the various groups comprises 3 to 6 animals.
  • a comparison of FIGS. 15 a and 15 b shows that the treatment with superagonistic CD28-specific is distinctly more effective than the treatment with conventional mAbs.
  • FIG. 16 shows the results according to FIG. 15, however with a prophylactic treatment.
  • d-7 is a treatment 7 days before the immunization, d-21 21 days before the immunization. It can be seen that a resistant state can be achieved by multiplication of regulatory T cells with a treatment within one week before the immunization, not however with a treatment 3 weeks before the immunization.
  • FIG. 17 is based on an approach identical to FIG. 15, however treatment with JJ316 at day 0 and 4.
  • FIG. 17 a shows the course of the disease corresponding to the representation of FIG. 15 a .
  • FIG. 17 b shows electro-physical properties, namely speed of the stimulus transmission as a direct clinical parameter for the damage of the sciatic nerve.
  • the measurements were performed according to the documents Adlkofer et al., Nat. Genet., 11:274-280 (1995) and Heininger et al., Ann. Neurol., 19:44-49 (1986).
  • the pathological results can be seen by means of control groups in particular in the extension of the N1 and F latencies (see days 0 and 12, open symbols). In contrast, the latencies in the case of the animals treated with superagonistic CD28-specific mAbs (JJ316) remain nearly unchanged between day 0 and day 12 (full symbols).
  • FIG. 18 the results of a therapy of the passive or active adoptive transfer EAN (AT-EAN). This is not induced by immunization with the nerve antigen, as described above, but takes place by intravenous injection of an autoreactive CD4+ T cell clone with specificity for the P2 myelin antigen (8 ⁇ 10 6 , cell line G7) according to the document Stienekemeier et al., Brain, 122:523-535 (1999).
  • FIG. 18 a shows the course of the disease of a control group, under treatment with JJ316 at day 1 (d1) and treatment at day 3 (d3). It is notable that even after the beginning of the disease symptoms, i.e. treatment at day 3, the disease can be stopped.
  • FIG. 1 shows the course of the disease of a control group, under treatment with JJ316 at day 1 (d1) and treatment at day 3 (d3). It is notable that even after the beginning of the disease symptoms, i.e. treatment at day 3, the disease can be stopped.
  • d3
  • the infiltration of the nerves with T cells has been quantified for the three groups, and it can be seen that in the control group this leads to a damage to the nerves.
  • the T cell counts are considerably lower in case of a treatment with mAbs used according to the invention because of the induction of regulatory T cells.
  • CD4+CD25+++ T cells expanded by means of monoclonal antibodies according to the invention can even after expansion maintain their functional properties, e.g. the suppression of the proliferation of “conventional” T cells.
  • the CD4+ T cells from human peripheral mononuclear cells (PBMC) were purified by means of magnetic separation (negative depletion of CD8+, CD11b+, CD16+, CD19+, CD36+ and CD56+ cells; purity 95%). These cells were then loaded with a CD28-specific antibody and then with a PE-conjugated secondary antibody, sorted into CD4+CD25+++ and CD4+CD25 ⁇ T cells (see FIG.
  • FIG. 22 b shows that the number of cell divisions in the indicator cells was strongly reduced by the presence of the expanded CD4+CD25+++ T cells, whereas the CD4+CD25 ⁇ T cells showed a weak effect only.

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
US10/389,679 2002-03-13 2003-03-13 Use of a CD28 binding substance for making a pharmaceutical composition Abandoned US20040092718A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US11/585,484 US20070134240A1 (en) 2002-03-13 2006-10-24 Use of a CD28 binding substance for making a pharmaceutical composition
US12/251,039 US8389016B2 (en) 2002-03-13 2008-10-14 Use of a CD28 binding substance for making a pharmaceutical composition
US13/783,959 US20130266577A1 (en) 2002-03-13 2013-03-04 Use of a cd28 binding substance for making a pharmaceutical composition

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10212108A DE10212108A1 (de) 2002-03-13 2002-03-13 Verwendung einer an CD28 bindenden Wirksubstanz zur Herstellung einer pharmazeutischen Zusammensetzung
DEDE10212108.7 2002-03-13

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/585,484 Continuation US20070134240A1 (en) 2002-03-13 2006-10-24 Use of a CD28 binding substance for making a pharmaceutical composition

Publications (1)

Publication Number Publication Date
US20040092718A1 true US20040092718A1 (en) 2004-05-13

Family

ID=27797912

Family Applications (5)

Application Number Title Priority Date Filing Date
US10/507,798 Abandoned US20060188493A1 (en) 2002-03-13 2003-03-13 Use of an active substance that binds to cd28 for producing a pharmaceutical composition
US10/389,679 Abandoned US20040092718A1 (en) 2002-03-13 2003-03-13 Use of a CD28 binding substance for making a pharmaceutical composition
US11/585,484 Abandoned US20070134240A1 (en) 2002-03-13 2006-10-24 Use of a CD28 binding substance for making a pharmaceutical composition
US12/251,039 Expired - Fee Related US8389016B2 (en) 2002-03-13 2008-10-14 Use of a CD28 binding substance for making a pharmaceutical composition
US13/783,959 Abandoned US20130266577A1 (en) 2002-03-13 2013-03-04 Use of a cd28 binding substance for making a pharmaceutical composition

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US10/507,798 Abandoned US20060188493A1 (en) 2002-03-13 2003-03-13 Use of an active substance that binds to cd28 for producing a pharmaceutical composition

Family Applications After (3)

Application Number Title Priority Date Filing Date
US11/585,484 Abandoned US20070134240A1 (en) 2002-03-13 2006-10-24 Use of a CD28 binding substance for making a pharmaceutical composition
US12/251,039 Expired - Fee Related US8389016B2 (en) 2002-03-13 2008-10-14 Use of a CD28 binding substance for making a pharmaceutical composition
US13/783,959 Abandoned US20130266577A1 (en) 2002-03-13 2013-03-04 Use of a cd28 binding substance for making a pharmaceutical composition

Country Status (5)

Country Link
US (5) US20060188493A1 (fr)
EP (1) EP1483293A2 (fr)
AU (1) AU2003221604A1 (fr)
DE (1) DE10212108A1 (fr)
WO (1) WO2003078468A2 (fr)

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060286104A1 (en) * 2005-05-11 2006-12-21 Tegenero Ag Superagonistic anti-CD28 antibodies
US20090104190A1 (en) * 2003-03-21 2009-04-23 John Wijdenes Humanized anti-cd4 antibody with immunosuppressive properties
US7851598B2 (en) 2004-01-09 2010-12-14 Isis Innovation Limited Receptor modulators
US20110059083A1 (en) * 2008-03-13 2011-03-10 Silke Aigner Agent for treating disease
US20110059082A1 (en) * 2008-03-13 2011-03-10 Matthias Germer Agent for treating disease
US20110059084A1 (en) * 2008-03-13 2011-03-10 Frank Osterroth Agent for treating disease
US20110229465A1 (en) * 2008-09-29 2011-09-22 Frank Osterroth Composition for treating disease
US20120027759A1 (en) * 2001-04-20 2012-02-02 Lieping Chen Methods of enhancing t cell responsiveness
US8609625B2 (en) * 2011-06-24 2013-12-17 Taipei Veterans General Hospital Method for enhancing immune response in the treatment of infectious and malignant diseases
US20150376278A1 (en) * 2003-09-22 2015-12-31 Theramab Llc Use of a cd28 binding pharmaceutical substance for making a pharmaceutical composition with dose-dependent effect
US9995733B2 (en) 2009-11-30 2018-06-12 Biotest Ag Agents for treating disease
WO2018183929A1 (fr) 2017-03-30 2018-10-04 Progenity Inc. Traitement d'une maladie du tractus gastro-intestinal avec un agent immunomodulateur libéré à l'aide d'un dispositif ingérable
WO2019246312A1 (fr) 2018-06-20 2019-12-26 Progenity, Inc. Traitement d'une maladie du tractus gastro-intestinal avec un immunomodulateur
WO2019246317A1 (fr) 2018-06-20 2019-12-26 Progenity, Inc. Traitement d'une maladie ou d'un état dans un tissu provenant de l'endoderme
WO2020106754A1 (fr) 2018-11-19 2020-05-28 Progenity, Inc. Méthodes et dispositifs pour traiter une maladie à l'aide d'agents biothérapeutiques
WO2021119482A1 (fr) 2019-12-13 2021-06-17 Progenity, Inc. Dispositif ingérable pour administrer un agent thérapeutique dans le tractus gastro-intestinal
EP4252629A2 (fr) 2016-12-07 2023-10-04 Biora Therapeutics, Inc. Procédés, dispositifs et systèmes de détection du tractus gastro-intestinal

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10345008A1 (de) * 2003-09-22 2005-04-28 Tegenero Ag Verwendung einer an CD28 bindenden Wirksubstanz zur Herstellung einer pharmazeutischen Zusammensetzung mit dosisabhängiger Wirkung
DE10352900A1 (de) * 2003-11-11 2005-06-16 Tegenero Ag Verwendung einer an CD28 bindenden Wirksubstanz zur Herstellung einer pharmazeutischen Zusammensetzung zur Behandlung von B-CLL
ES2437571T3 (es) 2004-11-11 2014-01-13 Theramab Llc Anticuerpos anti-CD28 superagonistas
CA3103629A1 (fr) 2018-06-15 2019-12-19 Flagship Pioneering Innovations V, Inc. Augmentation de l'activite immunitaire par modulation de facteurs de signalisation post-cellulaires
EP3962493A2 (fr) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V, Inc. Métodes de modulation de l'activité immunitaire
JP2023509359A (ja) 2019-12-17 2023-03-08 フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド 鉄依存性細胞分解の誘導物質との併用抗癌療法
CA3184366A1 (fr) 2020-06-29 2022-01-06 Darby Rye Schmidt Virus modifies pour favoriser la thanotransmission et leur utilisation dans le traitement du cancer
WO2022040482A1 (fr) 2020-08-19 2022-02-24 Xencor, Inc. Compositions anti-cd28 et/ou anti-b7h3
EP4313109A1 (fr) 2021-03-31 2024-02-07 Flagship Pioneering Innovations V, Inc. Polypeptides de thanotransmission et leur utilisation dans le traitement du cancer
AU2022303363A1 (en) 2021-06-29 2024-01-18 Flagship Pioneering Innovations V, Inc. Immune cells engineered to promote thanotransmission and uses thereof
US20240059786A1 (en) * 2022-02-24 2024-02-22 Xencor, Inc. Anti-cd28 x anti-trop2 antibodies
WO2024077191A1 (fr) 2022-10-05 2024-04-11 Flagship Pioneering Innovations V, Inc. Molécules d'acide nucléique codant pour des trif et des polypeptides supplémentaires et leur utilisation dans le traitement du cancer

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5025825A (en) * 1990-06-15 1991-06-25 Moen Incorporated Riser spout diverter assembly
US5257824A (en) * 1991-12-30 1993-11-02 Eggen Harald I Extender for a plumbing mount with spring loaded sealing piston
US20030166860A1 (en) * 2001-12-04 2003-09-04 Thomas Hunig Peptide or protein containing a C '-D loop of the CD28 receptor family
US6987171B1 (en) * 1997-05-28 2006-01-17 Tegenero Gmbh Human CD28 specific monoclonal antibodies for antigen-non-specific activation of T-lymphocytes

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5591629A (en) * 1994-04-29 1997-01-07 Mayo Foundation For Medical Education & Research Monoclonal antibodies which promote central nervous system remyelination
CA2194814A1 (fr) * 1997-01-10 1998-07-10 Terry L. Delovitch Stimulation des cellules t protectrices pour prevenir les maladies auto-immunes
JP2004500095A (ja) * 2000-02-24 2004-01-08 エクサイト　セラピーズ，　インコーポレイテッド 細胞の同時の刺激および濃縮

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5025825A (en) * 1990-06-15 1991-06-25 Moen Incorporated Riser spout diverter assembly
US5257824A (en) * 1991-12-30 1993-11-02 Eggen Harald I Extender for a plumbing mount with spring loaded sealing piston
US6987171B1 (en) * 1997-05-28 2006-01-17 Tegenero Gmbh Human CD28 specific monoclonal antibodies for antigen-non-specific activation of T-lymphocytes
US20030166860A1 (en) * 2001-12-04 2003-09-04 Thomas Hunig Peptide or protein containing a C '-D loop of the CD28 receptor family

Cited By (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120027759A1 (en) * 2001-04-20 2012-02-02 Lieping Chen Methods of enhancing t cell responsiveness
US20100291676A1 (en) * 2003-03-21 2010-11-18 John Wijdenes Humanized anti-cd4 antibody with immunosuppressive properties
US20090208496A1 (en) * 2003-03-21 2009-08-20 John Wijdenes Humanized anti-cd4 antibody with immunosuppressive properties
US20090208497A1 (en) * 2003-03-21 2009-08-20 John Wijdenes Humanized anti-cd4 antibody with immunosuppressive properties
US8673304B2 (en) 2003-03-21 2014-03-18 Biotest Ag Humanized anti-CD4 antibody with immunosuppressive properties
US8586715B2 (en) 2003-03-21 2013-11-19 Biotest Ag Humanized anti-CD4 antibody with immunosuppressive properties
US9758581B2 (en) 2003-03-21 2017-09-12 Biotest Ag Humanized anti-CD4 antibody with immunosuppressive properties
US8685651B2 (en) * 2003-03-21 2014-04-01 Biotest Ag Method for screening for an anti-CD4 antibody suitable for use in immunotherapy
US8440806B2 (en) 2003-03-21 2013-05-14 Biotest Ag Humanized anti-CD4 antibody with immunosuppressive properties
US20090104190A1 (en) * 2003-03-21 2009-04-23 John Wijdenes Humanized anti-cd4 antibody with immunosuppressive properties
US20150376278A1 (en) * 2003-09-22 2015-12-31 Theramab Llc Use of a cd28 binding pharmaceutical substance for making a pharmaceutical composition with dose-dependent effect
US8945561B2 (en) 2004-01-09 2015-02-03 Isis Innovation Limited Receptor modulators
US7851598B2 (en) 2004-01-09 2010-12-14 Isis Innovation Limited Receptor modulators
US20110086049A1 (en) * 2004-01-09 2011-04-14 Isis Innovation Limited Receptor Modulators
US20060286104A1 (en) * 2005-05-11 2006-12-21 Tegenero Ag Superagonistic anti-CD28 antibodies
US8034585B2 (en) 2005-05-11 2011-10-11 Theramab Llc. Superagonistic anti-CD28 antibodies
US20110189735A1 (en) * 2005-05-11 2011-08-04 Theramab Llc. Superagonistic Anti-CD28 Antibodies
US7939638B2 (en) * 2005-05-11 2011-05-10 Theramab Llc. Superagonistic anti-CD28 antibodies
US20100168400A1 (en) * 2005-05-11 2010-07-01 Theramab Gmbh Superagonistic Anti-CD28 Antibodies
US8709414B2 (en) 2005-05-11 2014-04-29 Theramab Llc. Superagonistic anti-CD28 antibodies
US7585960B2 (en) * 2005-05-11 2009-09-08 Theramab Gmbh Nucleic acids encoding superagonistic anti-CD28 antibodies
US20110059084A1 (en) * 2008-03-13 2011-03-10 Frank Osterroth Agent for treating disease
US20110059082A1 (en) * 2008-03-13 2011-03-10 Matthias Germer Agent for treating disease
US9334325B2 (en) 2008-03-13 2016-05-10 Biotest Ag Method for treating psoriasis
US9512226B2 (en) 2008-03-13 2016-12-06 Biotest Ag Agent for treating disease
US9550831B2 (en) 2008-03-13 2017-01-24 Biotest Ag Method for treating psoriasis
US20110059083A1 (en) * 2008-03-13 2011-03-10 Silke Aigner Agent for treating disease
US20110229465A1 (en) * 2008-09-29 2011-09-22 Frank Osterroth Composition for treating disease
US9995733B2 (en) 2009-11-30 2018-06-12 Biotest Ag Agents for treating disease
US8609625B2 (en) * 2011-06-24 2013-12-17 Taipei Veterans General Hospital Method for enhancing immune response in the treatment of infectious and malignant diseases
EP4252629A2 (fr) 2016-12-07 2023-10-04 Biora Therapeutics, Inc. Procédés, dispositifs et systèmes de détection du tractus gastro-intestinal
WO2018183929A1 (fr) 2017-03-30 2018-10-04 Progenity Inc. Traitement d'une maladie du tractus gastro-intestinal avec un agent immunomodulateur libéré à l'aide d'un dispositif ingérable
EP4108183A1 (fr) 2017-03-30 2022-12-28 Biora Therapeutics, Inc. Traitement d'une maladie du tractus gastro-intestinal avec un agent immunomodulateur libéré à l'aide d'un dispositif ingérable
WO2019246317A1 (fr) 2018-06-20 2019-12-26 Progenity, Inc. Traitement d'une maladie ou d'un état dans un tissu provenant de l'endoderme
WO2019246312A1 (fr) 2018-06-20 2019-12-26 Progenity, Inc. Traitement d'une maladie du tractus gastro-intestinal avec un immunomodulateur
WO2020106754A1 (fr) 2018-11-19 2020-05-28 Progenity, Inc. Méthodes et dispositifs pour traiter une maladie à l'aide d'agents biothérapeutiques
WO2020106704A2 (fr) 2018-11-19 2020-05-28 Progenity, Inc. Dispositif ingestible pour administrer un agent therapeutique dans le tractus digestif
WO2020106750A1 (fr) 2018-11-19 2020-05-28 Progenity, Inc. Méthodes et dispositifs pour traiter une maladie au moyen d'une biothérapie
WO2020106757A1 (fr) 2018-11-19 2020-05-28 Progenity, Inc. Dispositif ingérable pour administrer un agent thérapeutique au tube digestif
WO2021119482A1 (fr) 2019-12-13 2021-06-17 Progenity, Inc. Dispositif ingérable pour administrer un agent thérapeutique dans le tractus gastro-intestinal
EP4309722A2 (fr) 2019-12-13 2024-01-24 Biora Therapeutics, Inc. Dispositif ingérable pour l'administration d'un agent thérapeutique au tractus gastro-intestinal

Also Published As

Publication number Publication date
EP1483293A2 (fr) 2004-12-08
WO2003078468A3 (fr) 2004-02-12
WO2003078468A2 (fr) 2003-09-25
US20130266577A1 (en) 2013-10-10
AU2003221604A8 (en) 2003-09-29
US20060188493A1 (en) 2006-08-24
AU2003221604A1 (en) 2003-09-29
DE10212108A1 (de) 2003-10-02
US20070134240A1 (en) 2007-06-14
US20090246204A1 (en) 2009-10-01
US8389016B2 (en) 2013-03-05

Similar Documents

Publication Publication Date Title
US8389016B2 (en) Use of a CD28 binding substance for making a pharmaceutical composition
TWI708787B (zh) Pd-1促效劑抗體及其用途
TWI795133B (zh) Ｂｃｍａ結合分子類及彼等之用途
AU2014361473B2 (en) PD-1 antibody, antigen-binding fragment thereof, and medical application thereof
CN108124445B (zh) Ctla4抗体、其药物组合物及其用途
WO2018205985A1 (fr) PROTÉINE DE FUSION CONTENANT UN RÉCEPTEUR DE TGF-β ET UTILISATIONS MÉDICALES ASSOCIÉES
KR101704865B1 (ko) 항-ox40 항체 및 그의 용도
JP7395471B2 (ja) 改変抗ＳＩＲＰａ抗体及びその使用
JP2023130380A (ja) Ｇｐｒｃ５ｄキメラ抗原受容体及びそれを発現する細胞
TWI823895B (zh) 抗b7-h4抗體、其抗原結合片段及其醫藥用途
TW201900679A (zh) 細胞毒性t淋巴球相關蛋白4 (ctla-4) 之新穎單株抗體
CN109414500A (zh) 治疗和诊断用pd-l1特异性单克隆抗体
CN104822704A (zh) 针对分化簇3(cd3)的人源化的抗体
KR20040036684A (ko) 치료용 결합 분자
KR101872746B1 (ko) 질병 치료용 제제
US20030166860A1 (en) Peptide or protein containing a C '-D loop of the CD28 receptor family
JP2021512107A (ja) 養子細胞療法およびチェックポイント阻害剤を使用する併用療法
CN110546165A (zh) 抗-pd-l1-抗-tim-3双特异性抗体
Heliopoulos et al. Therapeutic monoclonal antibodies and multiple sclerosis: the essentials
KR20230015348A (ko) Th2 개재성 질환을 치료 또는 예방하기 위한 PD-1 작용제 함유 의약 조성물

Legal Events

Date Code Title Description
AS Assignment

Owner name: TEGENERO AG, GERMANY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:HUNIG, THOMAS;REEL/FRAME:014205/0631

Effective date: 20030318

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION